TAK-779
SIGMA/SML0911 - ≥98% (HPLC)
Synonym: N,N-
CAS Number: 229005-80-5
Empirical Formula (Hill Notation): C33H39ClN2O2
Molecular Weight: 531.13
Linear Formula: C33H39ClN2O2
Product Type: Chemical
This image is provided for informative purposes only and does not represent an actual product label. It should not be used as a substitute for official product labeling.
This picture is provided solely for illustration purposes, it may have been created or edited with AI. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material.
This image depicts SML0911-5MG.
This image depicts SML0911-5MG.
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI | 1S/C33H38N2O2.ClH/c1-24-7 |
| InChI key | VDALIBWXVQVFGZ-UHFFFAOYSA |
| Quality Level | 100  |
| SMILES string | Cl.[N+](C5CCOCC5)(Cc1ccc( |
| solubility | H2O: 3 mg/mL, clear (warmed) |
| storage temp. | 2-8°C |
| Application: | TAK-779 has been used to inhibit CC chemokine ligand 5 (CCL5)– C-C chemokine receptor type 5 (CCR5) interaction in vitro in natural killer (NK) cytotoxicity assay. It has also been used as a blocker of CCR5 to study its effects and to evaluate the opening of the Panx-1 channels on peripheral blood mononuclear cells (PBMCs) isolated from human immunodeficiency virus (HIV)-infected individuals. |
| Biochem/physiol Actions: | TAK-779 inhibits human immunodeficiency virus (HIV) entrance by blocking the C-C chemokine receptor type 5 (CCR5). It also impairs the formation of atherosclerotic lesions by preventing T-helper 1 cells from entering the plaque. TAK-779 possesses anti-immunogenic properties. In an arthritis model, it could prevent the inflow of CCR5- and chemokine (C-X-C motif) receptor 3 (CXCR3)-positive T cells into inflamed joints. In mice, TTAK-779 protects the brain from focal cerebral ischemia. |
| Biochem/physiol Actions: | TAK-779 is a potent, dual antagonist at chemokine receptors C-C chemokine receptor type 2 (CCR2) and C-C chemokine receptor type 5 (CCR5) with IC50 = 1.4 nM at CCR5 and 2.3 nM at CCR2. Antagonists of both CCR2 and CCR5 such as TAK-779 have been investigated for treatment of viruses, rheumatoid arthritis, multiple sclerosis, and cancer. CCR5 is particularly targeted for anti-HIV therapy, since HIV entry into cells requires chemokine coreceptors CCR5 and C-X-C motif chemokine receptor 4 (CXCR4). |
| Biochem/physiol Actions: | TAK-779 is a potent, dual antagonist at chemokine receptors CCR2 and CCR5. |
| Packaging: | 5, 25 mg in glass bottle |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 51111800 |